Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 1Graft vs Host Disease 1

Interventions

Cyclophosphamide 54Tacrolimus 50Methotrexate 36Mycophenolic Acid 34fludarabine phosphate 33Busulfan 31Cyclosporine 29fludarabine 28Antilymphocyte Serum 28Melphalan 23Sirolimus 21Whole-Body Irradiation 18Radiotherapy 18Peripheral Blood Stem Cell Transplantation 18Methylprednisolone 18Filgrastim 15thymoglobulin 13Thiotepa 10Stem Cell Transplantation 9Rituximab 9Granulocyte Colony-Stimulating Factor 8Hematopoietic Stem Cell Transplantation 7Etoposide 7Cord Blood Stem Cell Transplantation 7Cytarabine 6Alemtuzumab 6ruxolitinib 5Transplantation 5Therapeutics 5Prednisone 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Graft vs Host Disease × belumosudil × Clear all
NCT07006506 2026-04-13

A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
46 enrolled
Other hematologic neoplasm

Graft vs Host Disease, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡